Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.68 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.68 |
| ▸ | AHR | P35869 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29690398 | 0.82 | EGFR (1.00) | EGFRERBB2AHR | |
| SCHEMBL30513 | 0.82 | EGFR (1.00) | EGFRERBB2AHR | |
| SCHEMBL159209 | 0.81 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL31060998 | 0.81 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL29350058 | 0.81 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL31060510 | 0.81 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL4586872 | 0.81 | EGFR (0.80) | EGFRERBB2AHR | |
| SCHEMBL14578431 | 0.81 | EGFR (0.72) | EGFRERBB2AHR | |
| SCHEMBL1262804 | 0.81 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL10108264 | 0.81 | EGFR (0.72) | EGFRERBB2AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109963871-A | Multivalence and multi-epitope Antibody and application method with agonist activity | 豪夫迈·罗氏有限公司 | 2019-07-02 | — | — | CN | disclosed |
| CN-109312407-A | Diagnostic and therapeutic method for cancer | 豪夫迈·罗氏有限公司 | 2019-02-05 | — | — | CN | disclosed |
| CN-109053891-A | A kind of anti-PD-L1 antibody and its preparation method and application | 苏州泓迅生物科技股份有限公司 | 2018-12-21 | — | — | CN | disclosed |
| CN-108697713-A | Methods for making tricyclic PI3K inhibitor compounds and methods of treating cancer therewith | 基因泰克公司 | 2018-10-23 | — | — | CN | disclosed |
| CN-108026110-A | Fused tricyclic compounds as kinases inhibitor | 国家公共部门基金会卡洛斯三世国家癌症研究中心(F.S.P.CNIO) | 2018-05-11 | — | — | CN | disclosed |
| CN-107912040-A | Pyrrolidine Amide Compounds As Histone Demethylase Inhibitors | 基因泰克公司 | 2018-04-13 | — | — | CN | disclosed |
| CN-107531690-A | The amines of 4,5,6,7 tetrahydrochysene 1H pyrazolos [4,3 c] pyridine 3 as CBP and/or EP300 inhibitor | 基因泰克公司 | 2018-01-02 | — | — | CN | disclosed |
| CN-107406414-A | (piperidin-3-yl) (naphthalen-2-yl) methanone derivatives and related compounds as inhibitors of histone demethylase KDM2B for the treatment of cancer | 基因泰克公司 | 2017-11-28 | — | — | CN | disclosed |
| CN-107406418-A | 4,5 glyoxalidine derivatives and its purposes as histone demethylase (KDM2B) inhibitor | 基因泰克公司 | 2017-11-28 | — | — | CN | disclosed |
| CN-107406429-A | Pyridazinone derivative and its purposes in treating cancer | 基因泰克公司 | 2017-11-28 | — | — | CN | disclosed |
| CN-101023100-B | Her2 antibody composition | GENENTECH INC | 2012-08-29 | — | — | CN | disclosed |
| CN-102612374-A | A method of promoting dendritic spine density | HOFFMANN LA ROCHE | 2012-07-25 | — | — | CN | disclosed |
| CN-102356092-A | Bispecific anti-her antibodies | GENENTECH INC | 2012-02-15 | — | — | CN | disclosed |
| CN-102216331-A | Method of treatment | HOFFMANN LA ROCHE | 2011-10-12 | — | — | CN | disclosed |
| CN-102124336-A | Method for screening for compounds that inhibit neurodegeneration | GENENTECH INC | 2011-07-13 | — | — | CN | disclosed |
| CN-102014913-A | Combination therapy with C-MET and EGFR antagonists | GENENTECH INC | 2011-04-13 | — | — | CN | disclosed |
| CN-101981056-A | Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof | GENENTECH INC | 2011-02-23 | — | — | CN | disclosed |
| CN-101616934-A | Suppress DR6 antibody and the purposes in treatment neuroscience illness thereof of DR6 in conjunction with APP | GENENTECH INC | 2009-12-30 | — | — | CN | disclosed |
| CN-101180072-A | Methods of using death receptor agonists and egfr inhibitors | GENENTECH INC (US) | 2008-05-14 | — | — | CN | disclosed |
| CN-101023100-A | HER2 antibody composition | GENENTECH INC | 2007-08-22 | — | — | CN | disclosed |